Alterome Therapeutics
Alterome Therapeutics is a clinical-stage, San Diego-based precision oncology company that uses its proprietary Kraken computational chemistry and machine learning platform to develop mutation-specific small-molecule inhibitors, currently advancing two Phase 1/1b assets targeting AKT1 E17K and pan-KRAS oncology populations.
- Company typePrivate
- Founded2022
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alterome Therapeutics does
Alterome Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California, developing alteration-specific targeted therapies for genetically defined oncology populations. The company's discovery engine is "The Kraken," a proprietary computational chemistry platform that combines structure-guided drug design with machine learning to engineer small molecules that selectively address specific oncogenic mutations rather than broad pathways. This mutation-specific approach is intended to expand the therapeutic index relative to traditional targeted oncology agents.
The pipeline comprises two first-in-class clinical-stage candidates, both in Phase 1/1b development. ALTA2618 is a mutation-specific AKT1 E17K inhibitor targeting a defined subset of solid tumors driven by that activating mutation, with first patient dosed in October 2024. ALTA3263 is positioned as a first-and-best-in-class pan-KRAS dual ON/OFF inhibitor, with first patient dosed in March 2025. The scientific advisory board includes investigators from Memorial Sloan Kettering, MD Anderson, Massachusetts General Hospital/Harvard, and Scripps, and leadership includes Board Chair Rich Heyman, CEO Jung Choi (appointed April 2025), and CMO Leonardo Faoro (appointed February 2026).
Alterome is pre-revenue and funds operations entirely through equity capital. Total funding exceeds $231 million across a $64 million Series A (January 2022), a $35 million Series A2 (November 2022), and a $132 million Series B (April 2024) led by Goldman Sachs Alternatives, with participation from OrbiMed, Vida Ventures, Nextech Invest, Driehaus Capital, Canaan Partners, Blue Owl, Invus, Boxer Capital, Colt Ventures, and Digitalis Ventures. In January 2025 the company added a partnership with Imagenomix Corp to apply AI tooling to clinical-trial operations. The company's business model is to advance mutation-specific oncology candidates through early-stage clinical proof-of-concept with the intent of partnering or further developing high-value assets; commercialization is not yet in scope.
Alterome Therapeutics firmographics
Firmographics- Name
- Alterome Therapeutics
- Legal name
- Alterome Therapeutics, Inc.
- Website
- https://alterome.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alterome Therapeutics is a clinical-stage, San Diego-based precision oncology company that uses its proprietary Kraken computational chemistry and machine learning platform to develop mutation-specific small-molecule inhibitors, currently advancing two Phase 1/1b assets targeting AKT1 E17K and pan-KRAS oncology populations.
- Ownership category
- akta.pro rank
Alterome Therapeutics industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- Oncology Specialty Pharmaceuticals
Keywords
Where Alterome Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alterome Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pipeline Development and Future Product Revenue: Pre-revenue clinical-stage company developing a pipeline of targeted oncology therapies. Revenue will be generated through commercialization of approved drug products following successful clinical development and regulatory approval. The company has raised over $231 million in venture capital funding to support clinical-stage development of ALTA2618 and ALTA3263.
- Potential Licensing and Partnership Deals: Biopharmaceutical companies may generate revenue through licensing agreements, co-development partnerships, or acquisition transactions as pipeline programs advance through clinical development toward regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Alterome Therapeutics product offering
Product offeringCore offering
Alterome Therapeutics is a clinical-stage precision oncology company developing alteration-specific small molecule targeted therapies for validated oncogenic drivers. Its pipeline includes two first-in-class drug candidates in Phase 1/1b trials: ALTA2618, a mutation-selective AKT1 E17K inhibitor for AKT-driven solid tumors, and ALTA3263, a pan-KRAS dual ON/OFF-state inhibitor for KRAS-mutant solid tumors, both designed using The Kraken computational chemistry platform.
Product overview
Alterome Therapeutics is a clinical-stage precision oncology company developing a pipeline of next-generation, small molecule targeted therapies for cancer treatment. The company's portfolio consists of two clinical-stage drug candidates: ALTA2618 (a mutation-specific AKT1 E17K inhibitor for AKT-driven cancers) and ALTA3263 (a pan-KRAS dual ON/OFF inhibitor for KRAS-driven cancers). Both programs leverage the company's structure-guided drug discovery approach to develop alteration-specific therapeutics that target disease-driving genetic mutations while sparing wild-type proteins, aiming to overcome the safety and efficacy limitations of earlier targeted therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- ALTA2618 A first-in-class, mutation-specific inhibitor of AKT1 E17K designed to treat AKT-driven cancers including breast, endometrial, and prostate cancers. Engineered for selectivity, potency, and a broad therapeutic index, it targets the mutant protein while sparing wild-type AKT isoforms and is in Phase 1/1b clinical development.
- ALTA3263 A first-and-best-in-class pan-KRAS dual ON/OFF inhibitor designed for broad, durable, and tolerable inhibition of KRAS-driven cancers. It targets KRAS while sparing HRAS and NRAS, demonstrating sub-1nM potency across over 90% of KRAS mutations including G12D, G12V, and wild-type KRAS, and is in Phase 1/1b clinical development.
Quantifiable outcome
- ALTA2618 targets up to 90% of AKT-activated cancers driven by the AKT1 E17K mutation while potentially eliminating AKT2-driven hyperglycemia toxicity seen with pan-AKT inhibitors
- +2 more outcomes
Companies that use Alterome Therapeutics
Customer profileSegments3 records
Ideal customer profiles2 records
Alterome Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alterome Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Imagenomix Corp.supportingAlterome partnered with Imagenomix Corp. in January 2025 to enhance precision oncology clinical trials with AI technology. This partnership aims to improve clinical trial efficiency and patient selection through artificial intelligence integration.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Alterome Therapeutics competitors and assessment
Company assessmentEmerging players
- Foghorn Therapeutics: Clinical-stage precision oncology company developing medicines targeting the chromatin regulatory system. Comparable as a platform-driven precision oncology biotech, though targeting different oncogenic mechanisms.
- Schrödinger: Computational drug discovery platform company with growing internal pipeline including precision oncology programs. Comparable to Alterome's structure-guided, ML-enabled small molecule discovery approach.
- ORIC Pharmaceuticals: Clinical-stage precision oncology company developing therapies targeting resistance mechanisms in cancer. Comparable biotech-stage peer with overlapping investor base (Alterome board member Dominic Piscitelli is CFO of ORIC).
Broad incumbents
- Amgen: Large biopharmaceutical company with Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor. Major established incumbent in the KRAS oncology space that Alterome's pan-KRAS program must differentiate against.
Direct peers
- Quanta Therapeutics: Clinical-stage precision oncology company focused on KRAS-driven cancers with allosteric inhibitors. Comparable to Alterome's mutation-selective KRAS approach; CMO Leonardo Faoro was previously CMO at Quanta.
- Mirati Therapeutics (Bristol Myers Squibb): Developed Krazati (adagrasib), a KRAS G12C inhibitor, now under Bristol Myers Squibb following acquisition. Directly comparable to Alterome's ALTA3263 pan-KRAS inhibitor as a competitor in the KRAS precision oncology space.
- Revolution Medicines: Clinical-stage precision oncology company developing RAS-targeted therapies, including the pan-RAS(ON) inhibitor RMC-6236. Directly comparable to Alterome as a competing developer of KRAS-targeted small molecules with a structure-based discovery approach.
- Erasca: Clinical-stage precision oncology company focused on the RAS/MAPK pathway. Highly comparable to Alterome's KRAS and AKT targeting strategy with multiple programs targeting oncogenic drivers in the same signaling cascade.
- Relay Therapeutics: Clinical-stage precision oncology company combining computational approaches with structural biology to develop targeted therapies. Comparable technology approach and oncology focus to Alterome's The Kraken platform.
- Scorpion Therapeutics: Clinical-stage precision oncology company developing small molecule therapies against high-value oncogenic targets, including PI3Kα and others. Closely comparable to Alterome's alteration-specific approach targeting validated oncogenic drivers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Alterome Therapeutics social profiles
Digital presenceAlterome Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alterome Therapeutics leadership team
Management profileNumber of profiles
Profiles21 records
Alterome Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alterome Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alterome Therapeutics
What does Alterome Therapeutics do?
Alterome Therapeutics is a clinical-stage precision oncology company developing alteration-specific small molecule targeted therapies for validated oncogenic drivers. Its pipeline includes two first-in-class drug candidates in Phase 1/1b trials: ALTA2618, a mutation-selective AKT1 E17K inhibitor for AKT-driven solid tumors, and ALTA3263, a pan-KRAS dual ON/OFF-state inhibitor for KRAS-mutant solid tumors, both designed using The Kraken computational chemistry platform.
Is Alterome Therapeutics a public or private company?
Alterome Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alterome Therapeutics founded?
Alterome Therapeutics was founded in 2022. It employs 11 to 50 people.
Where is Alterome Therapeutics based?
Alterome Therapeutics is headquartered in San Diego, United States, in the North America region.
How does Alterome Therapeutics make money?
Two revenue lines are on record. Pipeline Development and Future Product Revenue is the primary driver. The others are potential Licensing and Partnership Deals.
Who are Alterome Therapeutics's main competitors?
Emerging players on record are Foghorn Therapeutics, Schrödinger and ORIC Pharmaceuticals. Amgen is listed as a broad incumbent. Direct peers are Quanta Therapeutics, Mirati Therapeutics (Bristol Myers Squibb), Revolution Medicines, Erasca, Relay Therapeutics and Scorpion Therapeutics.
Does Alterome Therapeutics have an API?
No public API is recorded for Alterome Therapeutics.
What industry is Alterome Therapeutics in?
Alterome Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.